EpiAxis Therapeutics
Business Services · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
University Of Canberra, Australian Capit...Phone Number
+61 421012268Website
www.epiaxistherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About EpiAxis Therapeutics
EpiAxis Therapeutics is an investor-focused biotech company that develops reversible cyclic peptide inhibitors of LSD1 to combat treatment resistance in advanced cancers, including prostate, small cell lung, and colorectal cancers. The company aims to unlock the potential of existing therapies through LSD1 inhibition. They offer insights into their scientific research, technology platform, milestones, and collaboration opportunities. EpiAxis Therapeutics is dedicated to rewriting the fate of patients with advanced cancers.Explore more
EpiAxis Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EpiAxis Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if EpiAxis Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when EpiAxis Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at EpiAxis Therapeutics
Funding: Get notified immidiatlly once EpiAxis Therapeutics has new funding data
Check if EpiAxis Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
EpiAxis Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if EpiAxis Therapeutics is spiking on competitors!
Earning: See what the market has to say on EpiAxis Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined EpiAxis Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to EpiAxis Therapeutics
Compare insights from companies similar to EpiAxis Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
EpiAxis Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
EpiAxis Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about EpiAxis Therapeutics.
EpiAxis Therapeutics Tech Stack
A closer look at the technologies used by EpiAxis Therapeutics
See more technologies
EpiAxis Therapeutics News & Media
EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
SYDNEY & PITTSBURGH--(BUSINESS WIRE)--EpiAxis Therapeutics, a leading epigenetics company with a focus on the treatment, diagnosis and monitoring of cancer and the prevention of its recurrence, and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a collaboration to leverage AI for drug discovery to inhibit epigenetic oncologyEpiAxis Therapeutics Announces Positive Clinical Trial Data for its New Drug Program to Inhibit Metastatic Breast Cancer
EpiAxis Therapeutics has announced a pioneering clinical study, showing that an epigenetic inhibitor combined with chemotherapy can treat metastatic cancer. SYDNEY, AUSTRALIA, June 9, 2022 /EINPresswire.com/ -- EpiAxis Therapeutics has announced the …EpiAxis Therapeutics, A Leader in Novel Cancer Therapy, Announces the Appointment of Three New Non-Executive Directors
EpiAxis Therapeutics is a pioneering Australian pharma company that is advancing its epigenetic assets to target LSD1 as a treatment for metastatic cancer. SYDNEY, AUSTRALIA, July 27, 2020 /EINPresswire.com/ -- Following recent advances in its …
Read more news
Top Business Services Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding EpiAxis Therapeutics
Sign Up For FreeTo access detailed company insights
EpiAxis Therapeutics is an investor-focused biotech company that develops reversible cyclic peptide inhibitors of LSD1 to combat treatment resistance in advanced cancers, including prostate, small cell lung, and colorectal cancers. The company aims to unlock the potential of existing therapies through LSD1 inhibition. They offer insights into their... Read More
